Biblio Discovery — Demo Discovery Service

3 hasil untuk "Ravi Anantha"

Menampilkan 1–3 · 0,97 detik · RSS

  1. Artikel Jurnal

    ACAM2000 vaccine safety and immunogenicity considerations for smallpox and mpox

    Vanja Komlenovic; James McCarty; David Cassie dkk.

    Expert Review of Vaccines, Vol. 25 No. 1 · 2026 · Inggris · DOAJ Scopus

    Introduction Smallpox, eradicated globally in 1980, remains a major biodefense concern due to retained Variola virus stocks and the absence of population immunity following cessation of routine vaccination. Monkeypox virus (MPXV), a related orthopoxvirus, has reemerged as a global public health…

  2. Artikel Jurnal

    Passive transfer of human sera from chikungunya virus virus-like particle vaccine (Vimkunya) recipients fully protects non-human primates from viremia

    Christopher S. Morello; Ravi Anantha; Jason E. Comer dkk.

    npj Vaccines, Vol. 11 No. 1 · 2026 · Inggris · DOAJ Scopus

    Abstract Vimkunya, a chikungunya virus (CHIKV) virus-like particle (VLP) vaccine, is well-tolerated and induces a rapid, durable serum neutralizing antibody (SNA) response in individuals aged ≥12 years. This study evaluated the efficacy of human CHIKV VLP antisera to protect cynomolgus macaques…

  3. Artikel Jurnal

    A chikungunya virus-like particle vaccine reduces chikungunya disease in cynomolgus macaques and protection is mediated by antibody transferred from vaccinated humans

    Lark L. Coffey; Katherine J. Olstad; J. Rachel Reader dkk.

    npj Vaccines, Vol. 11 No. 1 · 2026 · Inggris · DOAJ Scopus

    Abstract Chikungunya virus (CHIKV) causes periodic outbreaks and is endemic in more than 110 countries. VIMKUNYA, a CHIKV virus-like particle (CHIKV VLP) vaccine, was recently approved by regulators in the United States, European Union, and United Kingdom. Efficacy of VIMKUNYA in endemic settings…